| Identification | Back Directory | [Name]
1H-Isoindole-1,3(2H)-dione, 5-[5-[[3-(4-broMophenyl)-2-iMino-4-oxo-5-thiazolidinylidene]Methyl]-2-furanyl]- | [CAS]
1420071-30-2 | [Synonyms]
CS-1259
BioyMifi
(DR5 ACTIVATOR)
Bioymifi (~90%)
Bioymifi >=98% (HPLC)
Bioymifi, 1420071-30-2
Bioymifi, DR5 Activator
Bioymifi,DR5 Activator, >95%
(Z)-5-(5-[(3-[4-Bromophenyl]-2-imino-4-oxothiazolidin-5-ylidene)methyl]furan-2-yl)isoindoline-1,3-dione
(E)-5-(5-((3-(4-bromophenyl)-2-imino-4-oxothiazolidin-5-ylidene)methyl)furan-2-yl)isoindoline-1,3-dione
1H-Isoindole-1,3(2H)-dione, 5-[5-[[3-(4-broMophenyl)-2-iMino-4-oxo-5-thiazolidinylidene]Methyl]-2-furanyl]-
5-[5-[[(5Z)-3-(4-Bromophenyl)-2-imino-4-oxo-5-thiazolidinylidene]methyl]-2-furanyl]-1H-isoindole-1,3(2H)-dione
1H-Isoindole-1,3(2H)-dione, 5-[5-[[(5Z)-3-(4-bromophenyl)-2-imino-4-oxo-5-thiazolidinylidene]methyl]-2-furanyl]-
(Z)-5-(5-((3-(4-bromophenyl)-2-imino-4-oxothiazolidin-5-ylidene)methyl)furan-2-yl)isoindoline-1,3-dione (Bioymifi)
Bioymifi 1H-Isoindole-1,3(2H)-dione, 5-[5-[[3-(4-broMophenyl)-2-iMino-4-oxo-5-thiazolidinylidene]Methyl]-2-furanyl]- | [Molecular Formula]
C22H12BrN3O4S | [MDL Number]
MFCD28118988 | [MOL File]
1420071-30-2.mol | [Molecular Weight]
494.32 |
| Chemical Properties | Back Directory | [density ]
1.75±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble2mg/mL, clear (warmed) | [form ]
powder | [pka]
9.62±0.20(Predicted) | [color ]
orange to dark orange red | [InChI]
1S/C22H12BrN3O4S/c23-12-2-4-13(5-3-12)26-21(29)18(31-22(26)24)10-14-6-8-17(30-14)11-1-7-15-16(9-11)20(28)25-19(15)27/h1-10,24H,(H,25,27,28)/b18-10-,24-22? | [InChIKey]
ULBOWKXOFOTCMU-NLDKGBHCSA-N | [SMILES]
S1\C(=C/c3[o]c(cc3)c4cc5c(cc4)C(=O)NC5=O)\C(=O)N(C1=N)c2ccc(cc2)Br |
| Safety Data | Back Directory | [Symbol(GHS) ]
GHS07 | [Signal word ]
Warning | [Hazard statements ]
H302-H317 | [Precautionary statements ]
P280 | [Hazard Codes ]
Xn | [Risk Statements ]
22 | [WGK Germany ]
3 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Acute Tox. 4 Oral |
| Hazard Information | Back Directory | [Description]
Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TNF-related apoptosis-inducing ligand (TRAIL or Apo2L), a member of this family, activates apoptosis in a variety of tumor cell lines by signaling through the death receptors, DR4 and DR5. Bioymifi directly activates DR5 (Kd = 1.2 μM; IC50 = 2 μM), inducing DR5 clustering, which leads to the initiation of FADD/caspase-8-dependent apoptosis in various cancer cells. | [Uses]
Bioymifi is thiazolidinone derivative that induces apoptosis. It is TRAIL receptor DR5 binding agent useful in human cancer cells. | [References]
[1] GELIN WANG. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells[J]. Nature chemical biology, 2012, 9 2: 84-89. DOI: 10.1038/nchembio.1153 |
|
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|